EU/3/17/1958:

Allogeneic umbilical cord blood CD34+ cells cultured ex vivo with Notch ligand Delta1 (dilanubicel)

Table of contents

Overview

This medicine is now known as dilanubicel.

On 17 January 2018, orphan designation (EU/3/17/1958) was granted by the European Commission to Voisin Consulting S.A.R.L, France, for allogeneic umbilical cord blood CD34+ cells cultured ex vivo with Notch ligand Delta1 (also known as NLA101) for treatment in haematopoietic stem cell transplantation.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in March 2021 on request of the Sponsor.

Key facts

Active substance
Allogeneic umbilical cord blood CD34+ cells cultured ex vivo with Notch ligand Delta1 (dilanubicel)
Intented use
Treatment in haematopoietic stem cell transplantation
Date of designation
17/01/2018
Orphan designation status
Withdrawn
EU designation number
EU/3/17/1958

Sponsor's contact details

Voisin Consulting S.A.R.L.
64, Avenue Pierre Grenier
92100 Boulogne Billancourt
France
Tel. +33 1 41 31 83 00
E-mail: orphan@voisinconsulting.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating